Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicks NyQuil is an over-the-counter combination medication developed by Procter & Gamble for the nighttime relief of common cold and influenza symptoms. It contains three active small molecule ingredients: acetaminophen, a pain reliever and fever reducer that inhibits cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2); dextromethorphan, an antitussive that acts as an agonist at sigma-1 receptors and an antagonist at NMDA receptors; and doxylamine succinate, a first-generation antihistamine that antagonizes histamine H1 receptors. The inclusion of doxylamine provides a sedating effect, making the formulation suitable for use before sleep to alleviate symptoms such as cough, sore throat, headache, minor aches, fever, runny nose, and sneezing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vicks NyQuil.